Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells

International Journal of Oncology

Volumn 29, Issue 1, 2006, Pages 269-278

  Zhou, Changlin ^a   Qiu, Lihua ^b   Sun, Yun ^b   Healey, Sarah ^a   Wanebo, Harold ^c   Kouttab, Nicola ^c   Di, Wen ^b   Yan, Bingfang ^d   Wan, Yinsheng ^a  

^a PROVIDENCE COLLEGE   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c ROGER WILLIAMS MEDICAL CENTER   (United States)

^d UNIVERSITY OF RHODE ISLAND   (United States)

Author keywords

AKT; EGFR; Ovarian cancer; PI3K; TSA

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; 4 ((3 BROMOPHENYL)AMINO) 6,7 DIMETHOXYQUINAZOLINE; 4-((3-BROMOPHENYL)AMINO)-6,7-DIMETHOXYQUINAZOLINE; BIRC5 PROTEIN, HUMAN; CHROMONE DERIVATIVE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE; HISTONE DEACETYLASE; HYDROXAMIC ACID; MICROTUBULE ASSOCIATED PROTEIN; MORPHOLINE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TRICHOSTATIN A; TUMOR PROTEIN;

ACETYLATION; ARTICLE; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; HUMAN; METABOLISM; OVARY TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ACETYLATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; MICROTUBULE-ASSOCIATED PROTEINS; MORPHOLINES; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 33845950849     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.1.269     Document Type: Article

References (53)

1. Yin BW and Lloyd KO: Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem 276: 27371-27375, 2001.
2. Greenlee RT, Hill-Harmon MB, Murray T and Thun M: Cancer statistics, 2001. CA Cancer J Clin 51: 15-36, 2001.
3. Nap M, Vitali A, Nustad K, Bast RC Jr, O'Brien TJ, Nilsson O, Seguin P, Suresh MR, Bormer OP, Saga T, De Bruijn HW, Nozawa S, Kreutz FT, Jette D, Sakahara H, Gadnell M, Endo K, Barlow EH, Warren D, Paus E, Hammarstrom S, Kenemans P and Hilgers J: Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. Tumour Biol 17: 325-331, 1996. (Pubitemid 26356807)
4. Auersperg N, Pan J, Grove BD, Peterson T, Fisher J, Maines-Bandiera S, Somasiri A and Roskelley CD: E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc Natl Acad Sci USA 96: 6249-6254, 1999.
5. Shin HJ, Baek KH, Jeon AH, Kim SJ, Jang KL, Sung YC, Kim CM and Lee CW: Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation. Oncogene 22: 3853-3858, 2003.
6. Inoue H, Shiraki K, Ohmori S, Sakai T, Deguchi M, Yamanaka T, Okano H and Nakano T: Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. Int J Mol Med 9: 521-525, 2002.
7. Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287-299, 2002.
8. Williams RJ: Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin Investig Drugs 10: 1571-1573, 2001.
9. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ and Ford CD: Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 1: 1181-1190, 2002.
10. Fenic I, Sonnack V, Failing K, Bergmann M and Steger K: In vivo effects of histone-deacetylase inhibitor trichostatin-A on murine spermatogenesis. J Androl 25: 811-818, 2004.
11. Ailenberg M and Silverman M: Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression. Biochem Biophys Res Commun 298: 110-115, 2002.
12. Rosato RR and Grant S: Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 13: 21-38, 2004.
13. Eickhoff B, Germeroth L, Stahl C, Kohler G, Ruller S, Schlaak M and van der Bosch J: Trichostatin A-mediated regulation of gene expression and protein kinase activities: reprogramming tumor cells for ribotoxic stress-induced apoptosis. Biol Chem 381: 1127-1132, 2000.
14. Maxhimer JB, Reddy RM, Zuo J, Cole GW, Schrump DS and Nguyen DM: Induction of apoptosis of lung and esophageal cancer cells treated with the combination of histone deacetylase inhibitor (trichostatin A) and protein kinase C inhibitor (calphostin C). J Thorac Cardiovasc Surg 129: 53-63, 2005.
15. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW and Burgess AW: Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 284: 31-53, 2003.
16. Earp HS, Dawson TL, Li X and Yu H: Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35: 115-132, 1995.
17. Sibilia M, Fleischmann A, Behrens A, Stingl L, Carroll J, Watt FM, Schlessinger J and Wagner EF: The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell 102: 211-220, 2000.
18. Gschwind A, Fischer OM and Ullrich A: The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4: 361-370, 2004.
19. Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K and Stetler-Stevenson WG: Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 93: 1375-1384, 2001.
20. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
21. Qiu L, Wang Q, Di W, Jiang Q, Schefeller E, Derby S, Wanebo H, Yan B and Wan Y: Transient activation of EGFR/AKT cell survival pathway and expression of survivin contribute to reduced sensitivity of human melanoma cells to betulinic acid. Int J Oncol 27: 823-830, 2005.
22. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I and Koeffler HP: Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101: 2760-2770, 2004.
23. Ono S, Oue N, Kuniyasu H, Suzuki T, Ito R, Matsusaki K, Ishikawa T, Tahara E and Yasui W: Acetylated histone H4 is reduced in human gastric adenomas and carcinomas. J Exp Clin Cancer Res 21: 377-382, 2002.
24. Liu LT, Chang HC, Chiang LC and Hung WC: Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 63: 3069-3072, 2003.
25. Kim MS, Son MW, Kim WB, In Park Y and Moon A: Apicidin, an inhibitor of histone deacetylase, prevents H-ras-induced invasive phenotype. Cancer Lett 157: 23-30, 2000.
26. Qiu L, Di W, Jiang Q, Scheffler E, Derby S, Yang J, Kouttab N, Wanebo H, Yan B and Wan Y: Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol 27: 1441-1448, 2005.
27. Roberts D, Schick J, Conway S, Biade S, Laub PB, Stevenson JP, Hamilton TC, O'Dwyer PJ and Johnson SW: Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br J Cancer 92: 1149-1158, 2005.
28. Akimoto T, Hunter NR, Buchmiller L, Mason K, Ang KK and Milas L: Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 5: 2884-2890, 1999.
29. Ivanov VN and Hei TK: Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway. Oncogene 24: 616-626, 2005.
30. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF and Guillou PJ: Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer 86: 886-892, 2002.
31. Huang HC, Liu YC, Liu SH, Tzang BS and Lee WC: Gel-danamycin inhibits trichostatin A-induced cell death and histone H4 hyperacetylation in COS-7 cells. Life Sci 70: 1763-1775, 2002.
32. Yasui W, Oue N, Ono S, Mitani Y, Ito R and Nakayama H: Histone acetylation and gastrointestinal carcinogenesis. Ann NY Acad Sci 983: 220-231, 2003.
33. Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I and Coombes RC: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971-976, 2001.
34. Della Ragione F, Criniti V, Della Pietra V, Borriello A, Oliva A, Indaco S, Yamamoto T and Zappia V: Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett 499: 199-204, 2001.
35. Eickhoff B, Ruller S, Laue T, Kohler G, Stahl C, Schlaak M and van der Bosch J: Trichostatin A modulates expression of p21waf1/cip1, Bcl-xL, ID1, ID2, ID3, CRAB2, GATA-2, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells. Biol Chem 381: 107-112, 2000.
36. Ferrara FF, Fazi F, Bianchini A, Padula F, Gelmetti V, Minucci S, Mancini M, Pelicci PG, Lo Coco F and Nervi C: Histone deacetylase-targeted treatment restores retinoic acid signaling and differentiation in acute myeloid leukemia. Cancer Res 61: 2-7, 2001.
37. Andl CD, Mizushima T, Nakagawa H, Oyama K, Harada H, Chruma K, Herlyn M and Rustgi AK: Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem 278: 1824-1830, 2003.
38. Citri A, Kochupurakkal BS and Yarden Y: The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3: 51-60, 2004.
39. Nicosia SV, Bai W, Cheng JQ, Coppola D and Kruk PA: Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am 17: 927-943, 2003.
40. Zhang P, Chan J, Dragoi AM, Gong X, Ivanov S, Li ZW, Chuang TH, Tuthill C, Wan Y, Karin M and Chu WM: Activation of IKK by thymosin alpha1 requires the TRAF6 signalling pathway. EMBO Rep 6: 531-537, 2005.
41. Sui L, Dong Y, Ohno M, Watanabe Y, Sugimoto K and Tokuda M: Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors. Int J Oncol 21: 315-320, 2002.
42. Olie RA, Simoes-Wust AP, Baumann B, Leech SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 60: 2805-2809, 2000.
43. Ling X, Bernacki RJ, Brattain MG and Li F: Induction of survivin expression by taxol (paclitaxel) is an early event, which is independent of taxol-mediated G2/M arrest. J Biol Chem 279: 15196-15203, 2004.
44. Inoue A and Fujimoto D: Histone deacetylase from calf thymus. Biochim Biophys Acta 220: 307-316, 1970.
45. Vidali G, Boffa LC and Allfrey VG: Properties of an acidic histone-binding protein fraction from cell nuclei. Selective precipitation and deacetylation of histones F2A1 and F3. J Biol Chem 247: 7365-7373, 1972.
46. Kikuchi H and Fujimoto D: Multiplicity of histone deacetylase from calf thymus. FEBS Lett 29: 280-282, 1973.
47. Csordas A: On the biological role of histone acetylation. Biochem J 265: 23-38, 1990.
48. Allegra P, Sterner R, Clayton DF and Allfrey VG: Affinity chromatographic purification of nucleosomes containing transcriptionally active DNA sequences. J Mol Biol 196: 379-388, 1987.
49. Hebbes TR, Thorne AW and Crane-Robinson C: A direct link between core histone acetylation and transcriptionally active chromatin. EMBO J 7: 1395-1402, 1988.
50. Tazi J and Bird A: Alternative chromatin structure at CpG islands. Cell 60: 909-920, 1990.
51. Roth SY and Allis CD: Histone acetylation and chromatin assembly: a single escort, multiple dances? Cell 87: 5-8, 1996.
52. Pazin MJ and Kadonaga JT: What's up and down with histone deacetylation and transcription? Cell 89: 325-328, 1997.
53. Toh Y, Ohga T, Endo K, Adachi E, Kusumoto H, Haraguchi M, Okamura T and Nicolson GL: Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas. Int J Cancer 110: 362-367, 2004.